Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Salivary Gland

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    127 result(s) found for: Salivary Gland. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2014-001274-34 Sponsor Protocol Number: SG-ABI14 Start Date*: 2014-07-03
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant, salivary gland cancers.
    Medical condition: relapsed and/or metastatic, castration resistant, salivary gland cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10026677 Malignant salivary gland cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004408-36 Sponsor Protocol Number: HN02-UC-0130/1205 Start Date*: 2013-03-12
    Sponsor Name:UNICANCER
    Full Title:
    Medical condition: _
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10051975 Salivary gland carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-003227-21 Sponsor Protocol Number: SGC-AX14 Start Date*: 2014-10-21
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori Milano
    Full Title: Phase II study on Inlyta® (axitinib) in recurrent and/or metastatic salivary gland cancers (SGCs) of the upper aerodigestive tract
    Medical condition: recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10051975 Salivary gland carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004282-34 Sponsor Protocol Number: 2833 Start Date*: 2006-10-13
    Sponsor Name:Royal Marsden NHS Foundation Trust
    Full Title: A phase II study of bethanechol chloride to treat pseudomembranous candidosis in cancer patients with salivary gland dysfunction.
    Medical condition: Oral candidosis (pseudomembranous subtype)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000314-38 Sponsor Protocol Number: 1206-HNCG Start Date*: 2014-07-28
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expre...
    Medical condition: Salivary gland cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061934 Salivary gland cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) FR (Ongoing) NL (Completed) GB (GB - no longer in EU/EEA) HU (Completed) AT (Ongoing) GR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001794-32 Sponsor Protocol Number: UC-0130/1619 Start Date*: 2016-11-23
    Sponsor Name:UNICANCER
    Full Title: A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck.
    Medical condition: recurrent and/or metastatic salivary glands carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066882 Metastatic salivary gland cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-000348-24 Sponsor Protocol Number: CVB2018-1 Start Date*: 2018-06-11
    Sponsor Name:Department of Otorhinolaryngology, Head and Neck Surgery
    Full Title: Mesenchymal stem cells for radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients (MESRIX-II)
    Medical condition: The trial will include participants with Xerostomia (International Classification of Diseases-10: DQ 838A) who have been treated with raditherapy for a head and neck cancer prevoiusly.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10013781 Dry mouth PT
    20.0 10017947 - Gastrointestinal disorders 10048223 Xerostomia LLT
    20.0 100000004865 10039420 Salivary gland therapeutic procedures HLT
    20.0 10017947 - Gastrointestinal disorders 10039404 Salivary gland conditions HLGT
    21.1 10017947 - Gastrointestinal disorders 10039390 Salivary gland atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000682-30 Sponsor Protocol Number: 01-09.02.15. Start Date*: 2015-04-27
    Sponsor Name:Tartu University Hospital
    Full Title: Botulinum neurotoxin type A treatment for sialorrhea in central nervous system diseases
    Medical condition: Hypersalivation
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10020746 Hypersalivation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000682-36 Sponsor Protocol Number: NL65109.091.18 Start Date*: 2018-07-05
    Sponsor Name:Radboud university medical center
    Full Title: The efficacy of cabozantinib in advanced salivary gland cancer patients, a phase II clinical trial
    Medical condition: Salivary gland cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001249-15 Sponsor Protocol Number: 314-12-401 Start Date*: 2013-11-07
    Sponsor Name:Otsuka Novel Products GmbH
    Full Title: A Two-Part Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients with Advanced Cancers that are Poorly Responsive ...
    Medical condition: • Advanced prostate cancer • Advanced epithelial ovarian cancer, advanced squamous cell carcinoma of the cervix, advanced breast cancer, endometrial cancer, and salivary gland cancer that are p...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061934 Salivary gland cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041848 Squamous cell carcinoma of the cervix PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003856-19 Sponsor Protocol Number: CVB2018-2 Start Date*: 2019-01-09
    Sponsor Name:Department of Otorhinolaryngology, Head and Neck Surgery and Audiology. Rigshospitalet, University Hospital of Cph, DK
    Full Title: A Phase I Open Label Study Evaluating the Safety and Feasibility of Allogeneic Mesenchymal stem cells for radiation-induced hyposalivation and xerostomia in previous oropharyngeal patients
    Medical condition: The trial will include participants with Xerostomia ( International Classification of Diseases-10: DQ 838A)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10048223 Xerostomia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002093-40 Sponsor Protocol Number: 104902 Start Date*: 2017-08-30
    Sponsor Name:Radboudumc
    Full Title: 68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinoma
    Medical condition: Patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma or salivary duct carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022514-47 Sponsor Protocol Number: NV25409 Start Date*: 2011-09-05
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients
    Medical condition: Treatment and prevention of CMV disease in kidney transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004862 10049107 CMV viraemia LLT
    16.0 100000004862 10009703 CMV infection LLT
    16.0 100000004848 10009701 CMV LLT
    16.0 100000004862 10060577 CMV viremia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) FR (Ongoing) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-021691-28 Sponsor Protocol Number: DAMS-7 Start Date*: 2011-11-04
    Sponsor Name:Hospital Vall d'Hebron
    Full Title: PILOT CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF BOTULINUM NEUROTOXIN TYPE- A IN SALIVARY GLANDS IN THE TREATMENT OF CHRONIC DROOLING IN PATIENTS WITH CEREBRAL PALSY: A CONTROLLED CLINIC...
    Medical condition: Hypersalivation (chronic sialorrhea)in patients with cerebral palsy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10039424 Salivary hypersecretion PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003857-27 Sponsor Protocol Number: LUPSA Start Date*: 2020-01-23
    Sponsor Name:Radboudumc
    Full Title: 177Lu-PSMA Radioligand Therapy for advanced salivary gland cancer, a phase II pilot study.
    Medical condition: Salivary gland cancer. More specifically two subtypes: adenoid cystic carcinoma and salivary duct carcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000066-22 Sponsor Protocol Number: BAY 43-9006 Start Date*: 2008-04-30
    Sponsor Name:Christie Hospital NHS Foundation Trust
    Full Title: A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic Carcinoma
    Medical condition: advanced salivary adenoid cystic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053231 Adenoid cystic carcinoma PT
    9.1 10051975 Salivary gland carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016668-35 Sponsor Protocol Number: HBO-CPH1 Start Date*: 2009-12-22
    Sponsor Name:Copenhagen University Hospital
    Full Title: Hyperbaric Oxygen - a new treatment modality in patients with salivary gland radiation injury
    Medical condition: Late radiation tissue injury to salivary glands
    Disease: Version SOC Term Classification Code Term Level
    12.0 10013781 Dry mouth LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001586-87 Sponsor Protocol Number: RSLV-132-04 Start Date*: 2016-09-29
    Sponsor Name:Resolve Therapeutics, LLC
    Full Title: A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren’s Syndrome
    Medical condition: Primary Sjogrens Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001720-19 Sponsor Protocol Number: XRS-ITRT-2018 Start Date*: 2018-12-12
    Sponsor Name:Institut de Terapia Regenerativa Tissular S.L. (ITRT)
    Full Title: Phase II clinical trial to evaluate the effect and safety of MSV * in Xerostomia * adult autologous bone marrow mesenchymal stem cells, expanded under GMP of IBGM
    Medical condition: Xerostomia post radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10048223 Xerostomia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004532-30 Sponsor Protocol Number: MRZ60201_3091_1 Start Date*: 2014-12-09
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of...
    Medical condition: Chronic troublesome sialorrhea associated with neurological disorders (e.g. cerebral palsy, traumatic brain injury) and/or intellectual disability in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    19.0 10017947 - Gastrointestinal disorders 10039424 Salivary hypersecretion PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 02 06:36:52 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA